Bellicum Pharmaceuticals, Inc. has entered into a non-exclusive, royalty-bearing licensing agreement with ARIAD Pharmaceuticals Inc. (Nasdaq: ARIA) for its ARGENT™ cell-signaling regulation technology.
The terms of agreement include:
The Bellicum product candidates will use AP1903, ARIAD's small molecule dimerizer drug, which already has passed a Phase 1 clinical trial.
According to Bellicum CEO Tom Farrell:
"We are delighted that ARIAD has selected Bellicum to advance the dimerizer technology. We have assembled a compelling set of preclinical data, and completion of this license now allows us to move rapidly to clinical development of our first cancer vaccine."
Bellicum Pharmaceuticals, Inc. is focused on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for cancer treatment. The company's lead product candidate, BP-GMAX-CD1, is a novel dendritic cell vaccine to treat prostate cancer.
Find more details from the press release at PR NEwswire at ARIAD Pharma, Inc.
Comment Preview